SCHEMBL4332228

SCHEMBL4332228

CCCOc1c(C(=O)NCc2ccco2)ccc2[nH]nc(-c3cc4ccccc4o3)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 8/20 0.46
USP2 O75604 3/20 0.46
ALOX15 P16050 2/20 0.46
MAPT P10636 4/20 0.44
HPGD P15428 7/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 3/20 0.42
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 5/20 0.41
NPC1 O15118 2/20 0.41
TP53 P04637 2/20 0.41
HTT P42858 2/20 0.41
RAB9A P51151 2/20 0.41
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4343252 0.90 HSD17B10 (0.49) HSD17B10USP2ALOX15MAPTHPGD
SCHEMBL4336091 0.84 HSD17B10 (0.52) HSD17B10USP2ALOX15MAPTHPGD
SCHEMBL2861468 0.83 JAK2 (0.44) MAPTLMNATSHRKDM4EALDH1A1
SCHEMBL2867115 0.82 PIP5K1C (0.45) MAPTKDM4EALDH1A1NPC1TP53
SCHEMBL4346837 0.80 MKNK1 (0.46) HSD17B10MAPTLMNAKDM4EALDH1A1
SCHEMBL4346677 0.80 TACR3 (0.40) JAK2JAK3MAPK1
SCHEMBL13636099 0.80 TACR3 (0.40) JAK2JAK3MAPK1
SCHEMBL4327612 0.79 JAK2 (0.40) HSD17B10ALOX15MAPTHPGDTSHR
SCHEMBL4331838 0.78 HPGD (0.53) HSD17B10HPGDKDM4EALDH1A1NPC1
SCHEMBL4332984 0.77 KDM4E (0.40) HSD17B10MAPTHPGDKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 HSD17B10 1699/4885USP2 3607/4885ALOX15 3445/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 HSD17B10 1699/4885USP2 3607/4885ALOX15 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.